


Andolast

Cat. No.:	HY-106358A
CAS No.:	143330-46-5
Molecular Formula:	C ₁₅ H ₁₁ N ₉ Na ₂ O
Molecular Weight:	379.29
Target:	Phosphodiesterase (PDE)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



SOLVENT & SOLUBILITY

In Vitro

DMSO : 11.36 mg/mL (29.95 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent		1 mg	5 mg	10 mg
	Concentration	Mass			
	1 mM		2.6365 mL	13.1825 mL	26.3650 mL
	5 mM		0.5273 mL	2.6365 mL	5.2730 mL
	10 mM		0.2637 mL	1.3183 mL	2.6365 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Andolast (CR 2039) is an anti-allergic agent. Andolast can inhibit cAMP-phosphodiesterase with an IC₅₀ value of 50 μM. Andolast can be used for the research of asthma^[1].

In Vivo

Andolast (CR 2039) (i.v. or i.m.) inhibits rat passive cutaneous anaphylaxis (PCA) with an ED₅₀ of 0.1 mg/kg^[1]. CR 2039 (10-100 mg/kg; i.v. or i.m.) inhibits the microvascular permeability changes in a model of allergic conjunctivitis in sensitized guinea-pigs^[1]. CR 2039 (0-1000 μM; i.v.) inhibits dose dependently guinea-pig lung cAMP-phosphodiesterase with an IC₅₀ value of 50 μM^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Hartley guinea-pigs (300-500 g) ^[1]
Dosage:	10-100 mg/kg
Administration:	I.M; I.V.
Result:	Showed dose-related significant protection against IgE-dependent bronchial anaphylaxis

induced by aerosolized antigen in anesthetized guinea-pigs.
Delayed dose dependently the onset of bronchoconstriction induced by aerosolized antigen.

REFERENCES

- [1]. Revel L, Colombo S, Ferrari F, Folco G, Rovati LC, Makovec F. CR 2039, a new bis-(1H-tetrazol-5-yl)phenylbenzamide derivative with potential for the topical treatment of asthma. *Eur J Pharmacol.* 1992;229(1):45-53.
- [2]. Czuczwar SJ, Gasior M, Kozicka M, Pietrasiewicz T, Turski WA, Kleinrok Z. A potential anti-asthmatic drug, CR 2039, enhances the anticonvulsive activity of some antiepileptic drugs against pentetrazol in mice. *Eur Neuropsychopharmacol.* 1998;8(3):233-238.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA